{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:06:34Z","timestamp":1772046394389,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["KG081048"],"award-info":[{"award-number":["KG081048"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["KG081048"],"award-info":[{"award-number":["KG081048"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["KG081048"],"award-info":[{"award-number":["KG081048"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s10637-018-0700-z","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T01:14:01Z","timestamp":1546650841000},"page":"345-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study"],"prefix":"10.1007","volume":"37","author":[{"given":"Clinton","family":"Yam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Esteva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miral M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshara S.","family":"Raghavendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish S.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly H.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Chavez Mac Gregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Griner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Ching J.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"issue":"5","key":"700_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamaoncol.2015.1546","volume":"1","author":"ML Neuhouser","year":"2015","unstructured":"Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, Ochs-Balcom HM, Thomson CA, Caan BJ, Tinker LF, Urrutia RP, Knudtson J, Anderson GL (2015) Overweight, obesity, and postmenopausal invasive breast Cancer risk: a secondary analysis of the Women's Health Initiative randomized clinical trials. JAMA Oncol 1(5):611\u2013621. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1546","journal-title":"JAMA Oncol"},{"issue":"4","key":"700_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1467-789X.2006.00261.x","volume":"7","author":"AR Carmichael","year":"2006","unstructured":"Carmichael AR (2006) Obesity and prognosis of breast cancer. Obes Rev 7(4):333\u2013340. https:\/\/doi.org\/10.1111\/j.1467-789X.2006.00261.x","journal-title":"Obes Rev"},{"issue":"8","key":"700_CR3","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/1055-9965.EPI-05-0106","volume":"14","author":"MK Whiteman","year":"2005","unstructured":"Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomark Prev 14(8):2009\u20132014. https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0106","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"700_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jjco\/hym023","volume":"37","author":"B Demirkan","year":"2007","unstructured":"Demirkan B, Alacacioglu A, Yilmaz U (2007) Relation of body mass index (BMI) to disease free (DFS) and distant disease free survivals (DDFS) among Turkish women with operable breast carcinoma. Jpn J Clin Oncol 37(4):256\u2013265. https:\/\/doi.org\/10.1093\/jjco\/hym023","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"700_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1467-789X.2004.00142.x","volume":"5","author":"DP Rose","year":"2004","unstructured":"Rose DP, Komninou D, Stephenson GD (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5(3):153\u2013165. https:\/\/doi.org\/10.1111\/j.1467-789X.2004.00142.x","journal-title":"Obes Rev"},{"issue":"2","key":"700_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1210\/jcem-36-2-207","volume":"36","author":"JM Grodin","year":"1973","unstructured":"Grodin JM, Siiteri PK, MacDonald PC (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36(2):207\u2013214. https:\/\/doi.org\/10.1210\/jcem-36-2-207","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"700_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.mce.2004.08.002","volume":"229","author":"A Mawson","year":"2005","unstructured":"Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B (2005) Estrogen and insulin\/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229(1\u20132):161\u2013173. https:\/\/doi.org\/10.1016\/j.mce.2004.08.002","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"700_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/mp.54.3.149","volume":"54","author":"J Dupont","year":"2001","unstructured":"Dupont J, Le Roith D (2001) Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 54(3):149\u2013154","journal-title":"Mol Pathol"},{"issue":"4","key":"700_CR9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.bbrc.2006.09.116","volume":"350","author":"L Bernard","year":"2006","unstructured":"Bernard L, Legay C, Adriaenssens E, Mougel A, Ricort JM (2006) Estradiol regulates the insulin-like growth factor-I (IGF-I) signalling pathway: a crucial role of phosphatidylinositol 3-kinase (PI 3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 350(4):916\u2013921. https:\/\/doi.org\/10.1016\/j.bbrc.2006.09.116","journal-title":"Biochem Biophys Res Commun"},{"key":"700_CR10","doi-asserted-by":"publisher","unstructured":"Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Fraser Symmans W, Lee MH, Yeung SC (2014) Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst 106(7). https:\/\/doi.org\/10.1093\/jnci\/dju158","DOI":"10.1093\/jnci\/dju158"},{"issue":"4","key":"700_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/erm.10.22","volume":"10","author":"PJ Wysocki","year":"2010","unstructured":"Wysocki PJ, Wierusz-Wysocka B (2010) Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn 10(4):509\u2013519. https:\/\/doi.org\/10.1586\/erm.10.22","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"700_CR12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4161\/cc.8.6.7933","volume":"8","author":"IN Alimova","year":"2009","unstructured":"Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8(6):909\u2013915. https:\/\/doi.org\/10.4161\/cc.8.6.7933","journal-title":"Cell Cycle"},{"issue":"13","key":"700_CR13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1200\/JCO.2016.69.7722","volume":"35","author":"A Sonnenblick","year":"2017","unstructured":"Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E (2017) Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast Cancer: analysis from the ALTTO phase III randomized trial. J Clin Oncol 35(13):1421\u20131429. https:\/\/doi.org\/10.1200\/JCO.2016.69.7722","journal-title":"J Clin Oncol"},{"issue":"20","key":"700_CR14","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","volume":"27","author":"S Jiralerspong","year":"2009","unstructured":"Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297\u20133302. https:\/\/doi.org\/10.1200\/JCO.2009.19.6410","journal-title":"J Clin Oncol"},{"issue":"6","key":"700_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"issue":"1","key":"700_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-012-1977-9","volume":"71","author":"FJ Esteva","year":"2013","unstructured":"Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC (2013) Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63\u201372. https:\/\/doi.org\/10.1007\/s00280-012-1977-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"700_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"12","key":"700_CR18","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol 25(12):2357\u20132362. https:\/\/doi.org\/10.1093\/annonc\/mdu456","journal-title":"Ann Oncol"},{"issue":"17","key":"700_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625\u20131638. https:\/\/doi.org\/10.1056\/NEJMoa021423","journal-title":"N Engl J Med"},{"issue":"1","key":"700_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/j.1550-8528.1998.tb00314.x","volume":"6","author":"A Lee","year":"1998","unstructured":"Lee A, Morley JE (1998) Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6(1):47\u201353","journal-title":"Obes Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0700-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:30:58Z","timestamp":1678559458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0700-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0700-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"19 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FJE has received honoraria from Novartis and Pfizer for consultancy. MCM has received honoraria for serving on the advisory boards of Roche and Pfizer and has received institutional research funding from Novartis. SCJY has received research funding and grant support from Bristol-Myers Squibb and DepoMed. GNH was the principal investigator of the BOLERO-2 trial and received research funding from Norvatis for conducting the trial and honoraria for chairing the protocol steering committee. VV has received honoraria from Novartis for consultancy. All other authors declare no relevant potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}